This randomized controlled trial analyzed data from the Women's Health Initiative (WHI) to assess the impact of hormone therapy (HT) on cardiovascular disease (CVD) risk based on age and time since menopause. The study included 27,347 postmenopausal women aged 50 to 79 years, randomized to receive HT or placebo. Findings
